CD4 and hepatocellular carcinoma: In another model, BALB/c mice with BNL hepatocellular carcinoma (HCC) tumors treated with dendritic cells (DC) fused with BNL cells (DC/BNL) and systemically administered interleukin-12 (IL-12) successfully rejected tumor, and CD4+ T cells appear to be the critical effectors, in that CD4+, but not CD8+, T cell depletion entirely reversed the antitumor effect (37).